<DOC>
	<DOCNO>NCT00840320</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability repeat dose compound 1278863A healthy subject .</brief_summary>
	<brief_title>Repeat Dose Safety Study Compound Treat Anemia</brief_title>
	<detailed_description>Compound 1278863A novel small molecule agent , stimulate erythropoiesis inhibition hypoxia-inducible factor ( HIF ) -prolyl hydroxylases ( EGLNs ) . This compound develop treatment anemia . Compound 111427 first administration compound 1278863A investigate safety , tolerability , pharmacokinetics , pharmacodynamics single oral dos 300 mg healthy adult subject . This study , PHI112842 , first administration compound 1278863A investigate safety , tolerability , pharmacokinetics , pharmacodynamics repeat oral dos 300 mg 14 day healthy adult subject . At least 6 subject complete cohort . Multiple blood sample pharmacokinetic analysis obtain post-dose cohort . Safety assess measurement vital sign , cardiac monitoring , collection adverse event assessment laboratory safety test . Blood sample collect pharmacodynamic analysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>1 . Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . 2 . Male female 18 55 year age , inclusive . 3 . A female subject must nonchildbearing potential . 4 . Male subject must agree use one acceptable contraception method list protocol 5 . Body weight great equal 50 kg BMI within range 19 31 kg/m2 ( inclusive ) . 6 . Capable give write informed consent 7 . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 1 . The subject positive prestudy drug screen . 2 . A hemoglobin value screening : Male subject postmenopausal female : &gt; 15.5 g/dL Female subject : &gt; 14.5 g/dL 3 . The value hematological parameter screen : MCV : outside reference range clinically significant deem investigator GSK Medical Monitor 4 . The value follow test screen : TIBC : outside reference range Serum iron : outside reference range Serum ferritin : outside reference range 5 . A value screen great upper limit reference range follow clinical laboratory parameter : AST , ALT , direct bilirubin . 6 . Clinically significant abnormal CPK determine investigator GSK Medical Monitor . 7 . Calculated creatinine clearance : &lt; 60mL/min 8 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 9 . A positive test HIV antibody . 10 . History drug abuse dependence within 6 month study . 11 . History regular alcohol consumption within 6 month study 12 . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . 13 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study drug 14 . History sensitivity study drug , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 15 . History sensitivity heparin heparininduced thrombocytopenia . ( clinical research unit use heparin maintain intravenous cannula patency ) 16 . Subjects preexist condition interfere normal gastrointestinal anatomy motility , and/or hepatic function could interfere absorption , metabolism , and/or excretion study drug . 17 . History peptic ulcer disease . 18 . History malignancy tumor . Nonmelanoma skin cancer definitely remove allow . 19 . Pregnant female determine positive serum urine hCG test screen prior dosing . 20 . Lactating female . 21 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 22 . Unwillingness inability follow procedure , lifestyle and/or dietary restriction outline protocol . 23 . Consumption red wine , seville orange , grapefruit grapefruit juice , exotic citrus fruit , grapefruit hybrid fruit juice prohibit fruit 7 day prior first dose study medication 24 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 25 . Exposure four new chemical entity within 12 month prior first dose day . 26 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
</DOC>